Exhibit 10.1

PATENT ASSIGNMENT AGREEMENT

THIS PATENT ASSIGNMENT AGREEMENT (the “Agreement”) is signed by the following
Parties and is effective as of 7th July, 2017 (the “Effective Date”):

1.

Zhengda Gene Life Science Shares Limited (“ZHENGDA”), a company incorporated in
the Hong Kong Special Administrative Region (“Hong Kong”) of the People’s
Republic of China (the “PRC”) with its registered address at Unit 04, 7/F.,
Bright Way Tower, No. 33 Mong Kok Road, Kowloon, Hong Kong.

2.

Medisun Precision Medicine Ltd. (“MPM”), a Marshall Islands Corporation with its
registered address at Trust Company Complex, Ajeltake Road, Majuro, Marshall
Islands MH96960.

ARTICLE 1 – BACKGROUND

1.1

ZHENGDA hereby warrants and confirms that it is the sole beneficial owner of
certain patent rights (the “Patent Rights”) applied for registration in the
State Intellectual Property Office of the PRC (patent application number:
201610218242) in relation to isolation and culture method for primary mice or
rat skeletal muscle cells.  A description of the Patent Rights is attached as
Appendix A to this Agreement.  ZHENGDA has the right to sell, assign and
transfer said Patent Rights.  It is hereby further warranted and confirmed by
ZHENGDA that it has obtained all necessary consents, permits and approvals to
acquire the Patent Rights, and now sells, assigns and transfers the Patent
Rights, and to the best information, knowledge and belief of ZHENGDA, there is
no litigation or dispute over the Patent Rights, and it is not aware that the
application would be likely to be refused by the State Intellectual Property
Office of the PRC.

1.2

ZHENGDA is willing to sell, assign and transfer said Patent Rights to MPM,
subject to the terms and conditions of this Agreement.

1.3

In consideration of the premises and the mutual covenants contained in this
Agreement, ZHENGDA and MPM (hereinafter the “Parties” or singularly a “Party”)
agree to the terms of this Agreement.

--------------------------------------------------------------------------------

ARTICLE 2 – ASSIGNMENT

2.1

Subject to the terms and conditions of this Agreement, ZHENGDA hereby sells,
assigns and transfers irrevocably unto MPM, its successors and assigns, the
entire interest in the said Patent Rights and all associated rights.  For the
Patent Rights assigned hereunder, MPM shall issue and allot 15,000,000 of its
new shares of common stock to ZHENGDA as consideration.

ARTICLE 3 – CLOSING

3.1

Closing of this Agreement shall take place on the Effective Date (the “Closing
Date”) and immediately after the signing of this Agreement by the Parties, in
which the following matters shall be transacted:

3.1.1

issue and allot 15,000,000 new shares of common stock of MPM to ZHENGDA; and

3.1.2

arrange to issue a share certificate of MPM to ZHENGDA certifying that ZHENGDA
is the holder of the said 15,000,000 new shares of common stock.

3.2

As soon as practicable after the Closing Date, the Parties shall use their best
endeavor to procure that the legal and beneficial ownership of the Patent Rights
be transferred or assigned to MPM, and the Parties shall execute all such
documents and conduct all such actions which are necessary to bring into effect
of such transfer or assignment. All the costs of such transfer or assignment
shall be borne equally between the Parties, unless otherwise agreed by the
Parties.

3.3

ZHENGDA shall use its best endeavour to assist and provide all such necessary
assistance required by MPM to complete the registration of the Patent Rights at
the State Intellectual Property Office of the PRC at its own costs.  The
obligation under this paragraph as well as the warranty in paragraph 1.1 shall
survive upon closing of this Agreement.

ARTICLE 4 – GENERAL

4.1

Unless with the written consent of the other party, the obligations or rights of
this Agreement cannot be modified or transferred.

--------------------------------------------------------------------------------

4.2

This Agreement supersedes all prior agreements between the parties who recognize
that any claim shall be made in respect of this Agreement. Any modifications to
this Agreement need to be in writing and signed by the Parties to become
effective.

4.3

This Agreement may be signed in any number of ways by the parties separately,
and signed and sent by email to the other party, be deemed an original, and all
separately signed documents (including some sent by email) should form the basis
of this Agreement.  There shall be three copies of this Agreement, with MPM
holding two and ZHENGDA holding one.

4.4

Except where otherwise specified, time is of the essence for this Agreement.

4.5

Unless the other party agrees or disclosure is required by law, regulation or in
response to a valid order of a court, no party shall disclose confidential
information (including but not limited to financial information, company and
customer data).   For avoidance of doubt, it is acknowledged by the Parties that
MPM is a public company whose shares have been listed for trading on the OTC
Markets in the United States of America, and hence MPM shall be permitted to
make all such disclosures or announcements which are necessary or required under
the applicable laws and regulations.  

4.6

If any jurisdiction finds any provision of this Agreement to be illegal, invalid
or unenforceable, it would not affect the legitimacy of the other provisions,
validity or enforceability.

4.7

The parties to this Agreement have been advised to obtain independent
professional advice.

4.8

Costs and expenses associated with the transfer of the Patent Rights shall be
borne by the respective Parties unless otherwise agreed.

4.9

This Agreement shall be governed by and construed in accordance with the PRC law
and the Parties to the Agreement have agreed to have non-exclusive jurisdiction
of the courts of the PRC.

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
by their respective authorized signatories as of the date first indicated above.

MEDISUN PRECISION MEDICINE LTD.

By: /s/ Lisha Huang                               

       

             Name:  Lisha Huang

Title: Director

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

ZHENGDA’S SIGNATURE PAGE FOLLOWS]

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
by their respective authorized signatories as of the date first indicated above.

ZHENGDA GENE LIFE SCIENCE SHARES LIMITED

By: /s/ Guofeng Yang                                  

Name:  Guofeng Yang

Title:  Director

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

--------------------------------------------------------------------------------

Appendix A

Description of the Patent Rights

[f1.jpg]

[f2.jpg]

[f3.jpg]

 

 

[f4.jpg]

 

[f5.jpg]